Autolus Therapeutics (AUTL) Financials

Autolus Therapeutics (NASDAQ: AUTL) continues to show meaningful top-line growth, but profitability and cash burn remain the key issues for investors. In Q1 2026, the company reported revenue of $26.2 million, up from $24.3 million in Q4 2025 and $8.98 million in Q1 2025. That’s a strong year-over-year improvement, though revenue is still small relative to costs.

Gross margin improved sharply versus the prior quarter. Q1 2026 gross profit was $1.65 million, versus a gross loss of $1.04 million in Q4 2025. However, operating expenses remained very high at $61.2 million, driven by SG&A of $40.0 million and R&D of $21.2 million, which led to a $59.5 million operating loss.

Bottom-line losses remain large. Net loss in Q1 2026 was $71.6 million, slightly better than the $90.3 million loss in Q4 2025, but still significantly negative. On a per-share basis, the company lost $0.27 in Q1 2026.

Cash generation from operations is still negative. Autolus used $65.3 million in operating cash in Q1 2026, which is broadly in line with prior quarters. The business continues to rely on non-cash adjustments, investment activity, and its balance sheet liquidity to fund operations.

Balance sheet liquidity remains a major strength. As of March 31, 2026, Autolus held $130.9 million in cash and equivalents and $98.5 million in short-term investments, plus $1.5 million in restricted cash. Total current assets were $368.8 million against current liabilities of $63.6 million, suggesting near-term liquidity is solid.

Equity is positive, but retained earnings are deeply negative. Total common equity was $108.8 million, while retained earnings stood at a deficit of $1.46 billion. That reflects years of accumulated losses, which is common for development-stage biotech companies but still highlights the long road to profitability.

The company’s recent trend is mixed: revenue is growing, but spending is still outpacing sales. Since Q1 2025, quarterly revenue has generally moved higher, while gross losses have narrowed and then improved. Even so, operating losses remain substantial because the cost structure is still far larger than revenue.

• Revenue growth is accelerating year over year — Q1 2026 revenue of $26.2 million was well above $9.0 million in Q1 2025.
• Gross profit turned positive — Q1 2026 posted $1.65 million of gross profit after a gross loss in Q4 2025.
• Large liquidity cushion — cash, equivalents, and short-term investments give the company room to operate near term.
• Current assets comfortably exceed current liabilities — this reduces immediate balance sheet stress.
• Operating cash burn remains high — Q1 2026 operating cash outflow was $65.3 million, similar to recent quarters.
• Non-cash adjustments continue to support reported losses — depreciation, amortization, and other adjustments are material but not enough to offset losses.
• Investment activity boosted cash this quarter — sales/maturity of investments helped produce positive investing cash flow.
• Operating losses are still very large — Q1 2026 operating loss was $59.5 million.
• Net losses remain substantial — the company lost $71.6 million in Q1 2026.
• Shareholders have endured heavy accumulated deficits — retained earnings remain deeply negative at $1.46 billion.

Overall, AUTL looks like a company with improving commercial traction but still a long way from consistent earnings or positive operating cash flow. For retail investors, the main question is whether revenue growth can continue to outpace the company’s high spending rate before cash resources need to be replenished again.